-- Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q1 Revenue $29.2M, vs. Street Est of $27.2M
7:03AM ET 5/04/2022 MT Newswires...
Quotes Snapshot > DCPH
Deciphera Pharmaceuticals Inc DCPH:NASDAQ
Last Price$13.46NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/29/22
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$12.60 (1)
Ask (Size)$15.00 (1)
Day Low / HighN/A - N/A
Volume1.00
Read more news Recent News
-- Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q1 Loss $-0.80, vs. Street Est of $-0.88
7:03AM ET 5/04/2022 MT Newswires...
Deciphera Pharmaceuticals Prices $150 Million Public Offering
3:00AM ET 4/27/2022 MT NewswiresDeciphera Pharmaceuticals (DCPH) priced an underwritten public offering of 5,251,239 shares of its common stock at $10.00 per share. The company is also...
Truist Securities Adjusts Deciphera Pharmaceuticals' Price Target to $11 from $10, Keeps Hold Rating
10:28AM ET 4/13/2022 MT NewswiresDeciphera Pharmaceuticals (DCPH) has an average rating of hold and price targets ranging from $6 to $17, according to analysts polled by Capital IQ. (MT...
View all Commentary and Analysis
Deciphera Pharmaceuticals (DCPH) Investor Presentation - Slideshow
5:05PM ET 6/03/2022 Seeking AlphaDeciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q1 2022 Results - Earnings Call Transcript
5:22AM ET 5/08/2022 Seeking AlphaDeciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now
4:35AM ET 2/11/2022 Seeking AlphaDeciphera Pharmaceuticals (DCPH) Investor Presentation - Slideshow
3:27AM ET 2/11/2022 Seeking AlphaCompany Profile
Business DescriptionDeciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA. View company web site for more details
| Address | 200 Smith Street Waltham, Massachusetts 02451 |
| Phone | +1.781.209.6400 |
| Number of Employees | 114 |
| Recent SEC Filing | 06/24/2022 8-K |
| President & Chief Executive Officer | Steven L. Hoerter |
| Chief Financial Officer, Treasurer & Executive VP | Tucker Kelly |
| Chief Scientific Officer & Executive VP | Daniel L. Flynn |
| Senior Vice President-Clinical Development | Rodrigo Ruiz Soto |
Company Highlights
| Price Open | $13.01 |
| Previous Close | $13.46 |
| 52 Week Range | $6.51 - 37.99 |
| Market Capitalization | $891.3 M |
| Shares Outstanding | 66.2 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/02/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$4.59 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -284.95% |
| Return on Equity | -81.39% |
Analyst Ratings as of 02/24/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |